文献速递妇科

卵巢癌幸存者继发恶性肿瘤风险:52,680例患者40余年随访分析

Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up.
PubMed 文献 · Gynecol Oncol · 2021-06-03

基于SEER数据库1975至2016年52,680例卵巢癌患者,评估继发恶性肿瘤风险并按治疗方式分层。6.4%患者发生继发恶性肿瘤,总体标准化发病比(SIR)1.13;放疗增加总体及膀胱继发风险,化疗增加白血病风险,年轻和非白人患者风险更高。

要点

  • 卵巢癌幸存者继发恶性肿瘤总体风险升高(O/E 1.13)。
  • 放疗者总体继发风险增高(O/E 1.42),膀胱癌风险尤其显著(O/E 2.81)。
  • 化疗者白血病风险增高(O/E 3.06),实体瘤继发风险在10-20年潜伏期最大。

核心结论

  • 卵巢癌后继发恶性肿瘤风险增加,且随治疗方式、种族、潜伏期和年龄而异。

研究设计与样本

  • 基于SEER数据库1975-2016年52,680例卵巢癌患者的回顾性队列分析。

主要发现

  • 3366例(6.4%)发生继发恶性肿瘤,总体O/E 1.13(p < .05)。
  • 接受放疗者总体继发风险O/E 1.42,未放疗者O/E 1.11(p < .05);膀胱O/E 2.81。
  • 接受化疗者白血病O/E 3.06,总体继发风险O/E 1.11 vs 未化疗1.14(p < .05)。
  • 实体瘤继发超额风险在潜伏期10-20年最大,<50岁患者风险最高,非白人高于白人。

临床怎么用

  • 结果可帮助制定卵巢癌确诊女性的继发恶性肿瘤筛查方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Survivors of ovarian cancer are at risk of developing a secondary malignancy (SM). We sought to evaluate the risk of developing SM, stratified by treatment modality. METHODS: Standardized incidence ratios (SIR, observed-to-expected [O/E] ratio) were assessed in 52,680 patients diagnosed with ovarian cancer between 1975 and 2016 in the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. RESULTS: Of the 52,680 patients, 3366 patients (6.4%) developed SM, which was more than the endemic rate (O/E 1.13; p < .05). Patients who received any radiation (RT) had an increased risk of overall SM compared to those who didn't (O/E 1.42 vs 1.11; p < .05), and specifically, in the bladder (O/E 2.81). Patients who received any chemotherapy (CT) had an increased risk of leukemia (O/E 3.06), and a similar risk of overall SM compared to those not treated with CT (O/E 1.11 vs 1.14; p < .05). The excess risk of developing a solid tumor SM was greatest at latencies of 10-20 years. Patients younger than 50 had the highest risk of developing SM. Non-White patients had a higher risk of SM compared to White patients. CONCLUSIONS: This is the largest study to examine the risk of SM in patients with ovarian cancer and has the longest follow-up. Risk of SM was increased after ovarian cancer and varied with treatment modality, race, latency, and age. These results may help inform SM screening protocols for women diagnosed with ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Casper AC, Parsons MW, Chipman J, et al. Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Gynecol Oncol. 2021. PMID: 34092413. doi:10.1016/j.ygyno.2021.05.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。